Literature DB >> 26883073

STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells.

Joshua D Jackson1, James M Markert2, Li Li1, Steven L Carroll3, Kevin A Cassady4.   

Abstract

UNLABELLED: Interferon-stimulated genes (ISG) encode diverse proteins that mediate intrinsic antiviral resistance in infected cells. Here it was hypothesized that malignant peripheral nerve sheath tumor (MPNST) cells resist the productive infection of oncolytic herpes simplex virus (oHSV) through activation of the JAK/STAT1 pathway and resultant upregulation of ISGs. Multiple human and mouse MPNST cells were used to explore the relationship between STAT1 activation and the productive infection of Δγ134.5 oHSVs. STAT1 activation in response to oHSV infection was found to associate with diminished Δγ134.5 oHSVs replication and spread. Multiday pretreatment, but not cotreatment, with a JAK inhibitor significantly improved viral titer and spread. ISG expression was found to be elevated prior to infection and downregulated when treated with the inhibitor, suggesting that the JAK/STAT1 pathway is active prior to infection. Conversely, upregulation of ISG expression in normally permissive cells significantly decreased oHSV productivity. Finally, a possible link between NF-κB pathway activation and ISG expression was established through the expression of inhibitor of kB (IκB) which decreased basal STAT1 transcription and ISG expression. These results demonstrate that basal ISG expression prior to infection contributes to the resistance of Δγ134.5 oHSVs in MPNST cells. IMPLICATIONS: Although cancer-associated ISG expression has been previously reported to impart resistance to chemotherapy and radiotherapy, these data show that basal ISG expression also contributes to oncolytic HSV resistance. Mol Cancer Res; 14(5); 482-92. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26883073      PMCID: PMC4867290          DOI: 10.1158/1541-7786.MCR-15-0427

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer.

Authors:  Uri Einav; Yuval Tabach; Gad Getz; Assif Yitzhaky; Ugur Ozbek; Ninette Amariglio; Shai Izraeli; Gideon Rechavi; Eytan Domany
Journal:  Oncogene       Date:  2005-09-22       Impact factor: 9.867

2.  Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.

Authors:  Wioleta Luszczek; Venugopalan Cheriyath; Tarek M Mekhail; Ernest C Borden
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

3.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.

Authors:  C M Perou; S S Jeffrey; M van de Rijn; C A Rees; M B Eisen; D T Ross; A Pergamenschikov; C F Williams; S X Zhu; J C Lee; D Lashkari; D Shalon; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

4.  Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.

Authors:  J J Ruotsalainen; M U Kaikkonen; M Niittykoski; M W Martikainen; C G Lemay; J Cox; N S De Silva; A Kus; T J Falls; J-S Diallo; F Le Boeuf; J C Bell; S Ylä-Herttuala; A E Hinkkanen; M J Vähä-Koskela
Journal:  Gene Ther       Date:  2014-09-18       Impact factor: 5.250

5.  Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth.

Authors:  Julia Schultz; Dirk Koczan; Ulf Schmitz; Saleh M Ibrahim; Dominik Pilch; Jenny Landsberg; Manfred Kunz
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

6.  Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.

Authors:  Yonatan Y Mahller; Fatima Rangwala; Nancy Ratner; Timothy P Cripe
Journal:  Pediatr Blood Cancer       Date:  2006-06       Impact factor: 3.167

7.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

8.  Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.

Authors:  S G Patterson; S Wei; X Chen; D A Sallman; D L Gilvary; B Zhong; J Pow-Sang; T Yeatman; J Y Djeu
Journal:  Oncogene       Date:  2006-05-01       Impact factor: 9.867

9.  Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.

Authors:  Kazuhiko Kurozumi; Jayson Hardcastle; Roopa Thakur; Ming Yang; Gregory Christoforidis; Giulia Fulci; Fred H Hochberg; Ralph Weissleder; William Carson; E Antonio Chiocca; Balveen Kaur
Journal:  J Natl Cancer Inst       Date:  2007-11-27       Impact factor: 13.506

Review 10.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

View more
  20 in total

1.  Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.

Authors:  Cole Peters; Max Paget; Kizito-Tshitoko Tshilenge; Dipongkor Saha; Slawomir Antoszczyk; Anouk Baars; Thomas Frost; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

Review 2.  Oncolytic herpes simplex virus interactions with the host immune system.

Authors:  Dipongkor Saha; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  Curr Opin Virol       Date:  2016-08-03       Impact factor: 7.090

3.  Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.

Authors:  Ross W Walton; Michael C Brown; Matthew T Sacco; Matthias Gromeier
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

4.  Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity.

Authors:  Liu Ying; Hu Cheng; Xu Wen Xiong; Lin Yuan; Zhang Hai Peng; Zhong Wen Wen; Liang Jian Ka; Xiao Xiao; Cai Jing; Tan Ya Qian; Gao Zhi Liang; Yan Guang Mei; Zhu Wen Bo; Peng Liang
Journal:  Oncotarget       Date:  2017-04-11

5.  Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.

Authors:  Mark A Currier; Les Sprague; Tilat A Rizvi; Brooke Nartker; Chun-Yu Chen; Pin-Yi Wang; Brian J Hutzen; Meghan R Franczek; Ami V Patel; Katherine E Chaney; Keri A Streby; Jeffrey A Ecsedy; Joe Conner; Nancy Ratner; Timothy P Cripe
Journal:  Oncotarget       Date:  2017-03-14

6.  Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.

Authors:  Kevin A Cassady; David F Bauer; Justin Roth; Melissa R Chambers; Trent Shoeb; Jennifer Coleman; Mark Prichard; G Yancey Gillespie; James M Markert
Journal:  Mol Ther Oncolytics       Date:  2017-03-01       Impact factor: 7.200

Review 7.  NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses-Therapeutic Perspectives.

Authors:  Justyna Struzik; Lidia Szulc-Dąbrowska
Journal:  Cancers (Basel)       Date:  2018-11-08       Impact factor: 6.639

8.  Constitutive Interferon Maintains GBP Expression Required for Release of Bacterial Components Upstream of Pyroptosis and Anti-DNA Responses.

Authors:  Beiyun C Liu; Joseph Sarhan; Alexander Panda; Hayley I Muendlein; Vladimir Ilyukha; Jörn Coers; Masahiro Yamamoto; Ralph R Isberg; Alexander Poltorak
Journal:  Cell Rep       Date:  2018-07-03       Impact factor: 9.423

Review 9.  New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.

Authors:  Kyle B Williams; David A Largaespada
Journal:  Genes (Basel)       Date:  2020-04-28       Impact factor: 4.141

Review 10.  Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance.

Authors:  Megha Budhwani; Roberta Mazzieri; Riccardo Dolcetti
Journal:  Front Oncol       Date:  2018-08-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.